Clinical Trial Update: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of Tuvusertib in combination with PLX038 in patients with advanced solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PLX038
• Tuvusertib (tuvusertib)

Snippet

Sponsor: Institut Curie | Conditions: Solid Tumor | Phase 1 | Status: TERMINATED